



(51) International Patent Classification:

A61K 31/403 (2006.01) C07D 209/88 (2006.01)
A61K 51/04 (2006.01)

(21) International Application Number:

PCT/EP2013/074986

(22) International Filing Date:

28 November 2013 (28.11.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

3689 /DEL/2012 30 November 2012 (30.11.2012) IN
1300647.3 15 January 2013 (15.01.2013) GB

(71) Applicant: **GE HEALTHCARE LIMITED** [GB/GB];
Amersham Place, Little Chalfont Buckinghamshire HP7
9NA (GB).

(72) Inventors: **NILSEN, Sondre**; GE Healthcare AS, Nycov-
eien 2, Postboks 4220, N-0401 Nydalen (NO). **BALAJI,
Srinath, Balaji, Aralikatti, Prahladachar**; S/O. Aralikatti
Prahladachar, Ganga Nilaya, Temple Street, Harapanahali-
583131, Davanagere-Dist Karnataka 583131 (IN). **MOKKAPATI,
Umamaheshwar, P**; H.No. 29-169,
Neredmet, N.V.Colony, R.K.Puram PO, Secunderabad-
500056., Andhra Pradesh 500056 (IN). **KADAVILPPAR-
AMPU, MOHAMED, Afsal, Mohammed**; Villa Number
88, Kammasandra Road, Electronic City PO, Bangalore,
Karnataka 583131 (IN).

(74) Agents: **BANNAN, Sally** et al.; GE Healthcare Limited,
Pollards Wood, Nightingales Lane, Chalfont St Giles
Buckinghamshire HP8 4SP (GB).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: CRYSTALLIZATION PROCESS OF TRICYCLIC INDOLE DERIVATIVES

(57) Abstract: The present invention relates to a composition comprising a tricyclic indole compound. The composition has a higher purity and better impurity profile than known compositions comprising said tricyclic indole compound and as a consequence has superior properties, particularly when said compound is destined for use in vivo as a therapeutic or diagnostic agent. Also provided by the present invention is a method to make the composition of the invention, a pharmaceutical composition comprising the composition of the invention, and use of the composition of the invention in a medical method.




Technical Field of the Invention

The present invention relates to a composition comprising a tricyclic indole compound. More specifically the present invention relates to wherein said composition has a more favourable impurity profile as compared with known compositions comprising said compound.

Description of Related Art

Tricyclic indole compounds are known in the art and have been reported to have application variously as melatonin antagonists (Davies 1998 J Med Chem; 41: 451-467), secretory phospholipase A₂ inhibitors (Anderson *et al* EP 0952149 A1), treatment for Alzheimer's disease (Wantanabe WO 99/25340), treatment of inflammatory diseases such as septic shock (Kinnick *et al* WO 03/014082 and WO 03/016277) and binders of high affinity to translocator protein (TSPO, formerly known as peripheral benzodiazepine receptor; Wadsworth *et al* (WO 2010/109007).


The synthesis of these tricyclic indole compounds comprises a condensation reaction between an aniline and a bromo oxocycloalkanecarboxylate, followed by cyclization in the presence of a zinc halide. One problem with this cyclization reaction is that more than one cyclized isomer can result, as illustrated in Scheme 1 below:



The incorrect isomer is formed when the R group reacts with the -OH. This incorrect

isomer has similar reactivity to the correct isomer and as a consequence when any further steps are taken to modify the correct isomer, a respective incorrect isomer is generated in the reaction mixture. This is particularly problematic if the resultant compound is intended for *in vivo* use, as the incorrect isomer will likely compete with
 5 the correct isomer for binding to the intended biological target.

In the method described by Kinnick *et al* (WO 03/014082), a chloro group was introduced at the R position illustrated in Scheme 1 with the aim of forcing the cyclization reaction to take place in just one way and result in only the correct cyclized isomer. This strategy was applied by Wadsworth *et al* (WO 2010/109007) in the
 10 cyclization reaction illustrated in Scheme 2 below (where Et = ethyl and Bz = benzyl):



Work up and chromatographic purification of the resultant reaction mixture was followed by removal of the chloro group and conversion of the ethyl to diethyl amine to obtain a key intermediate, which in turn was purified using crystallization from diethyl
 15 ether. Purity of the key intermediate was still only 71%. When investigating this particular reaction, the present inventors have found that the purified reaction mixture still contains an amount of the incorrect isomer, which is evidently difficult to remove.


There is therefore a need for a method to obtain these and similar tricyclic indole compounds where the amount of incorrect isomer is reduced or preferably eliminated.

Summary of the Invention

The present invention relates to a composition comprising a tricyclic indole compound wherein the quantity of an incorrect isomer in said composition is reduced. The composition therefore has a higher purity and better impurity profile than known
 5 compositions comprising said tricyclic indole compound and as a consequence has superior properties, particularly when said compound is destined for use *in vivo* as a therapeutic or diagnostic agent. Also provided by the present invention is a method to make the composition of the invention, a pharmaceutical composition comprising the composition of the invention, and use of the composition of the invention in a medical
 10 method.

Detailed Description of the Preferred Embodiments

In one aspect, the present invention provides a composition comprising a compound of Formula I:



15 wherein:

R¹ is hydrogen, C₁₋₃ alkyl, C₁₋₃ alkoxy, or halo;

R² is hydroxyl, halo, cyano, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ fluoroalkyl, or C₁₋₃ fluoroalkoxy;


R³ is -N-R⁷R⁸ wherein R⁷ and R⁸ are hydrogen, C₁₋₆ alkyl, C₇₋₁₀ arylalkyl or, together with R⁷, forms a nitrogen-containing C₄₋₆ aliphatic ring;

20 R⁴ is O, S, SO, SO₂ or CH₂;

R^5 is CH_2 , CH_2-CH_2 , $CH(CH_3)-CH_2$ or $CH_2-CH_2-CH_2$;

R^6 is $-A^1-R^9$ wherein A^1 is a bond or C_{1-10} alkylene, and R^9 is hydrogen, fluoro or a leaving group, or R^9 is the group $-O-R^{10}$ wherein R^{10} is hydrogen, C_{1-3} alkyl, C_{3-6} aryl, C_{7-10} arylalkyl, or a hydroxyl protecting group;

5 wherein said composition comprises no more than 1% of a compound of Formula II:



wherein R^2 to R^6 are as defined for Formula I.

The term “alkyl” used either alone or as part of another group is defined as any straight $-C_nH_{2n+1}$ group, branched $-C_nH_{2n+1}$ group wherein n is >3 , or cyclic $-C_nH_{2n-1}$ group
 10 where n is >2 . Non-limiting examples of alkyl groups include methyl, ethyl, propyl, isobutyl, cyclopropyl and cyclobutyl.

The term “alkoxy” refers to an alkyl group as defined above comprising an ether linkage, and the term “ether linkage” refers to the group $-C-O-C-$. Non-limiting examples of alkoxy groups include, methoxy, ethoxy, and propoxy.

15 The term “halo” or “halogen” is taken to mean any one of chloro, fluoro, bromo or iodo.

The term “hydroxyl” refers to the group $-OH$.

The term “cyano” refers to the group $-CN$.

The terms “fluoroalkyl” and “fluoroalkoxy” refer respectively to an alkyl group and an alkoxy group as defined above wherein a hydrogen is replaced with a fluoro.

The term “arylalkyl” refers to an aryl-substituted alkylene group wherein “aryl” refers to any molecular fragment or group which is derived from a monocyclic or polycyclic aromatic hydrocarbon, or a monocyclic or polycyclic heteroaromatic hydrocarbon and “alkylene” refers to a divalent linear $-C_nH_{2n}-$ group.

- 5 A “nitrogen-containing C₄₋₆ aliphatic ring” is a saturated C₄₋₆ alkyl ring comprising a nitrogen heteroatom. Examples include pyrrolidinyl, piperidinyl and morpholinyl rings.

The term “leaving group” refers to a molecular fragment that departs with a pair of electrons in heterolytic bond cleavage. Non-limiting examples of suitable leaving groups include halo groups selected from chloro, iodo, or bromo, aryl or alkyl sulfonates such
10 as tosylate, triflate, nosylate or mesylate.

The term “protecting group” is meant a group which inhibits or suppresses undesirable chemical reactions, but which is designed to be sufficiently reactive that it may be cleaved from the functional group in question to obtain the desired product under mild enough conditions that do not modify the rest of the molecule. Protecting groups are
15 well-known in the art and are discussed in detail in ‘Protective Groups in Organic Synthesis’, by Greene and Wuts (Fourth Edition, John Wiley & Sons, 2007). Non-limiting examples of suitable protecting groups for hydroxyl include acetyl ($-COCH_3$), benzoyl ($-COC_6H_5$), benzyl ($-CH_2C_6H_5$), β -methoxyethoxymethyl ether (MEM), dimethoxytrityl (DMT) and methoxymethyl ether (MOM).

- 20 In a first preferred embodiment R¹ is halo and in a second preferred embodiment R¹ is hydrogen. When R¹ is halo it is most preferably chloro or bromo, and especially preferably chloro.

In a preferred embodiment R² is halo, C₁₋₃ alkoxy or C₁₋₃ fluoroalkoxy, most preferably hydrogen, halo or C₁₋₃ alkoxy, especially preferably hydrogen, fluoro or methoxy, and
25 most especially preferably methoxy.

In a preferred embodiment, R³ is $-N-R^7R^8$ wherein R⁷ and R⁸ are C₁₋₆ alkyl or C₇₋₁₀ arylalkyl, most preferably wherein R⁷ and R⁸ are C₁₋₃ alkyl, especially preferably wherein R⁷ and R⁸ are both ethyl.

In a preferred embodiment R^4 is CH_2 .

In a preferred embodiment, R^5 is CH_2-CH_2 .

In a first preferred embodiment, R^6 is $-A^1-R^9$ wherein A^1 is C_{1-10} alkylene, most preferably C_{1-3} alkylene and especially preferably ethylene, and R^9 is the group $-O-R^{10}$ wherein R^{10} is C_{7-10} arylalkyl or a hydroxyl protecting group, most preferably wherein R^{10} is a hydroxyl protecting group.

In a second preferred embodiment R^6 is $-A^1-R^9$ wherein A^1 is C_{1-10} alkylene, most preferably C_{1-3} alkylene and especially preferably ethylene, and R^9 is hydrogen, fluoro or a leaving group. Where R^9 is fluoro it is preferably $[^{18}F]$ fluoro, such that the composition of the invention is an “*in vivo* imaging composition”. Where R^9 is a leaving group the composition of the invention is a “precursor composition” that can be reacted with $[^{18}F]$ fluoride to obtain the *in vivo* imaging composition. The leaving group is preferably halo, or an aryl or alkyl sulfonate, most preferably an aryl or alkyl sulfonate, and especially preferably tosylate, triflate, nosylate or mesylate.

The term “no more than” should be understood to mean any amount less than the quoted percent quantity. Therefore no more than 1% means any amount between 0-1%. In an ideal embodiment of the composition of the present invention there is 0% of said compound of Formula II in the composition of the invention. However, in reality, it may be that at least a trace amount of the compound of Formula II remains in the composition, i.e. no more than 1% could e.g. refer to 0.1-1%.

In a first preferred composition of the present invention:

R^1 is halo, preferably chloro or bromo, and most preferably chloro;

R^2 is halo, C_{1-3} alkoxy or C_{1-3} fluoroalkoxy, preferably hydrogen, halo or C_{1-3} alkoxy, most preferably hydrogen, fluoro or methoxy, and especially preferably methoxy;

R^3 is $-N-R^7R^8$ wherein R^7 and R^8 are C_{1-6} alkyl or C_{7-10} arylalkyl, preferably wherein R^7 and R^8 are C_{1-3} alkyl, most preferably wherein R^7 and R^8 are both ethyl;

R⁴ is CH₂;

R⁵ is CH₂-CH₂; and,

R⁶ is -A¹-R⁹ wherein A¹ is C₁₋₁₀ alkylene, most preferably C₁₋₃ alkylene and especially preferably ethylene, and R⁹ is the group -O-R¹⁰ wherein R¹⁰ is C₇₋₁₀ arylalkyl or a
 5 hydroxyl protecting group, preferably wherein R¹⁰ is a hydroxyl protecting group.

In a second preferred composition of the present invention:

R¹ is hydrogen;

R² is halo, C₁₋₃ alkoxy or C₁₋₃ fluoroalkoxy, preferably hydrogen, halo or C₁₋₃ alkoxy, most preferably hydrogen, fluoro or methoxy, and especially preferably methoxy;

10 R³ is -N-R⁷R⁸ wherein R⁷ and R⁸ are C₁₋₆ alkyl or C₇₋₁₀ arylalkyl, preferably wherein R⁷ and R⁸ are C₁₋₃ alkyl, most preferably wherein R⁷ and R⁸ are both ethyl;

R⁴ is CH₂;

R⁵ is CH₂-CH₂; and,


R⁶ is -A¹-R⁹ wherein A¹ is C₁₋₁₀ alkylene, most preferably C₁₋₃ alkylene and especially
 15 preferably ethylene, and R⁹ is hydrogen, fluoro, or a leaving group, preferably wherein R⁹ is fluoro or a leaving group, wherein said fluoro is [¹⁸F]fluoro and wherein said leaving group is preferably halo, or an aryl or alkyl sulfonate, most preferably an aryl or alkyl sulfonate, and especially preferably tosylate, triflate, nosylate or mesylate. This second preferred composition can therefore either be an *in vivo* imaging composition or
 20 a precursor composition of the invention.

The compound of Formula I and the compound of Formula II of the composition of the present invention as defined above may each comprise a chiral centre. All forms of such isomer, including enantiomers and diastereoisomers, are encompassed by the present invention. The compound of Formula I and the compound of Formula II may be present
 25 in the composition of the present invention as racemic mixture or as an enantiomerically-enriched mixture, or the racemic mixture may be separated using well-known techniques

and an individual enantiomer maybe used alone. Preferably, the composition of the invention comprises the S-enantiomer of said compound of Formula I and said compound of Formula II.


In a preferred embodiment, the composition of the present invention comprises no more than 0.5% of said compound of Formula II, most preferably no more than 0.3%, especially preferably no more than 0.2%, and most especially preferably no more than 0.1%.

In a particularly preferred composition of the present invention, said compound of Formula I is a compound of Formula Ia:



10 wherein each of R¹, R², R⁷, R⁸, R⁹ and A¹ are as variously defined hereinabove

and said compound of Formula II is a compound of Formula IIa:



wherein each of R^2 , R^7 , R^8 , R^9 and A^1 are as variously defined hereinabove.

Preferably for this particularly preferred composition of the invention:

R^1 is hydrogen;

5 R^2 is fluoro or methoxy;

R^7 and R^8 are C_{1-6} alkyl;

R^9 is hydrogen, fluoro or a leaving group; and,

A^1 is C_{1-10} alkylene.

Most preferably for this particularly preferred composition of the invention:

10 R^1 is hydrogen;

R^2 is methoxy;

R^7 and R^8 are C_{1-3} alkyl;

R^9 is [^{18}F]fluoro or an aryl or alkyl sulfonate; and,

A^1 is C_{1-3} alkylene.

15 Especially preferably for this particularly preferred composition of the invention:

R¹ is hydrogen;

R² is methoxy;

R⁷ and R⁸ are methyl or ethyl;

R⁹ is [¹⁸F]fluoro, tosylate, triflate, nosylate or mesylate; and,

5 A¹ is C₁₋₃ alkylene.

Most especially preferably for this particularly preferred composition of the invention:

R¹ is hydrogen;

R² is methoxy;

R⁷ and R⁸ are both ethyl;

10 R⁹ is [¹⁸F]fluoro or mesylate; and,

A¹ is ethylene.

Where an above-defined particularly preferred composition of the invention comprises ¹⁸F it is an *in vivo* imaging composition, and where it comprises a leaving group, it is a precursor composition.

15 In another aspect, the present invention comprises a method to obtain the composition as defined hereinabove wherein said method comprises crystallization of a reaction mixture comprising said compound of Formula I as defined hereinabove, and said compound of Formula II as defined hereinabove, wherein said crystallization is carried out in a suitable organic solvent in the presence of a catalytic amount of a weak organic base in order to
20 obtain said composition.

The term “catalytic amount” means an amount of a substance used in a chemical reaction as a catalyst and is generally much smaller than the stoichiometric amounts of either reactants or products.

The term “suitable organic solvent” encompasses non-polar solvents and polar aprotic


solvents, suitably having a dielectric constant of between 3.5-8. Examples of suitable organic solvents for use in the method of the present invention include diethyl ether, ethyl acetate, tetrahydrofuran (THF) and diisopropylether. Diethyl ether is preferred.

The term “weak organic base” refers to an organic compound which acts as a base.

- 5 Organic bases are generally proton acceptors and usually contain nitrogen atoms, which can easily be protonated. Amines and nitrogen-containing heterocyclic compounds are organic bases. Non-limiting examples include pyridine, alkyl amines, morpholine, imidazole, benzimidazole, histidine, phosphazene bases and hydroxides of some organic cations. In the context of the present invention alkyl amines are preferred, e.g. N,N-
10 diisopropyl amine, triethyl amine or diethyl amine.

- The present inventors have found that when using the method of the invention a very good quality product is obtained having optimum yield. Please refer to Example 1 wherein a method to obtain the composition of the present invention is described. It can be seen that by applying the method of the invention to the purification of a key
15 intermediate in the synthesis, the amount of incorrect isomer remaining is significantly less than when the prior art method for purification of this intermediate is used.

Preferably, the reaction mixture for use in the method of the invention is obtained using a method comprising cyclization of a compound of Formula III:



- 20 wherein:

R¹ is as suitably and preferably defined hereinabove;

R² is as suitably and preferably defined hereinabove;

R³ is as suitably and preferably defined hereinabove;

R⁴ is as suitably and preferably defined hereinabove;

R⁵ is as suitably and preferably defined hereinabove; and,

5 R⁶ is as suitably and preferably defined hereinabove;

wherein said cyclization is carried out by reaction of said compound of Formula III with a zinc halide.


It is preferred that said zinc halide is zinc chloride or zinc bromide, most preferably zinc chloride.

10 In a particularly preferred embodiment said zinc chloride is added lot-wise. The term “lot-wise” means introduction of a reagent to a reaction using more than one addition. In the context of the present invention said more than one addition comprises a first addition and a second addition wherein said second addition is carried out at least 6 hours after said first addition. Said lot-wise addition preferably further comprises a third
15 addition wherein said third addition is carried out said second addition.

Cyclization of said compound of Formula III is preferably carried out wherein R¹ is halogen, preferably chloro, and wherein R⁶ comprises a protecting group. This is to ensure that the cyclization reaction results in as much of the correct isomer as possible. The R¹ and R⁶ group can be converted subsequently using methods well-known to the
20 person skilled in the art to obtain other R¹ and R⁶ groups as defined above.

Compounds of Formula III can be obtained from commercial starting materials using or adapting methods described in the prior art. Reference is made in this regard to the teachings of Julia & Lenzi (Bulletin de la Société de France 1962: 2262-2263), Davies *et al* (J Med Chem 1998; 41: 451-467), Kinnick *et al* (WO 2003/014082 and WO
25 2003/016277), Anderson *et al* (EP0952149 B1) and Wadsworth *et al* (WO 2010/109007). In each of these publications compounds of Formula III are obtained by

condensation reaction between an aniline and a bromo oxocycloalkanecarboxylate as illustrated in Scheme 3 below:



Scheme 3

In the above scheme R' is an R³ group as defined herein, R'' is an R¹ and/or an R² group
 5 as defined herein, R''' is an R⁶ group as defined herein and n' is an integer of 1-3.

In another aspect, the present invention provides a pharmaceutical composition comprising the composition of the invention together with a biocompatible carrier suitable for mammalian administration.

The “biocompatible carrier” is a fluid, especially a liquid, in which the composition of the
 10 invention is suspended or dissolved, such that the pharmaceutical composition is physiologically tolerable, i.e. can be administered to the mammalian body without toxicity or undue discomfort. The biocompatible carrier is suitably an injectable carrier liquid such as sterile, pyrogen-free water for injection; an aqueous solution such as saline (which may advantageously be balanced so that the final product for injection is either
 15 isotonic or not hypotonic); an aqueous solution of one or more tonicity-adjusting substances (e.g. salts of plasma cations with biocompatible counterions), sugars (e.g. glucose or sucrose), sugar alcohols (e.g. sorbitol or mannitol), glycols (e.g. glycerol), or other non-ionic polyol materials (e.g. polyethyleneglycols, propylene glycols and the like). The biocompatible carrier may also comprise biocompatible organic solvents such
 20 as ethanol. Such organic solvents are useful to solubilise more lipophilic compounds or formulations. Preferably the biocompatible carrier is pyrogen-free water for injection, isotonic saline or an aqueous ethanol solution. The pH of the biocompatible carrier for intravenous injection is suitably in the range 4.0 to 10.5.

In a yet further aspect, the present invention provides for use of the pharmaceutical

composition of the invention in a medical method, wherein said medical method is preferably either a method for treatment or a method for diagnosis of a pathological condition. In particular, the pharmaceutical composition of the present invention is useful in the treatment or diagnosis of a pathological condition comprising inflammation.

5 Where the composition of the invention is an *in vivo* imaging composition as referred to above, i.e. wherein R⁶ comprises [¹⁸F]fluoro, the medical method is preferably a method of *in vivo* imaging comprising:

- (i) administering said pharmaceutical composition to a subject;
- (ii) detecting signals emitted by the [¹⁸F]fluoro comprised in said
10 pharmaceutical composition;
- (iii) generating an image representative of the location and/or amount of said signals.

The “subject” of the invention can be any human or animal subject. Preferably the subject of the invention is a mammal. Most preferably, said subject is an intact
15 mammalian body *in vivo*. In an especially preferred embodiment, the subject of the invention is a human.

“Administering” the in this *in vivo* imaging method is preferably carried out parenterally, and most preferably intravenously.

The “detecting” step of the method of the invention involves detection of signals emitted
20 by the [¹⁸F]fluoro by means of a detector sensitive to said signals, i.e. a positron-emission tomography (PET) detector.

The “generating” step of the method of the invention is carried out by a computer which applies a reconstruction algorithm to the acquired signal data to yield a dataset. This dataset is then manipulated to generate images showing the location and/or amount of
25 signals emitted by said [¹⁸F]fluoro.

The *in vivo* imaging composition of the invention is readily obtained by reaction with

[¹⁸F]fluoride of a precursor composition as defined above, i.e. a composition of the invention wherein R⁶ comprises a leaving group as defined hereinabove. [¹⁸F]-fluoride ion (¹⁸F[⊖]) is normally obtained as an aqueous solution from the nuclear reaction ¹⁸O(p,n)¹⁸F and is made reactive by the addition of a cationic counterion and the
5 subsequent removal of water. Removal of water is commonly carried out by application of heat and use of a solvent such as acetonitrile to provide a lower boiling azeotrope. A “cationic counterion” is a positively-charged counterion examples of which include large but soft metal ions such as rubidium or caesium, potassium complexed with a cryptand, or tetraalkylammonium salts. A preferred cationic counterion is a metal complex of a
10 cryptand, most preferably wherein said metal is potassium and wherein said cryptand is Kryptofix 222.

In another aspect the present invention provides the pharmaceutical composition of the invention for use in any of the above-defined medical methods.

In a yet further aspect, the present invention provides for use of the composition of the
15 invention in the manufacture of the pharmaceutical composition of the invention for use in any of the above-defined medical methods.

In a further aspect the present invention provides a kit suitable for making the *in vivo* imaging composition of the invention, wherein said kit comprises said precursor composition. A specialised kit, or “cassette”, may be used to prepare the *in vivo*
20 imaging composition of the present invention on an automated radiosynthesis apparatus. By the term “cassette” is meant a piece of apparatus designed to fit removably and interchangeably onto an automated radiosynthesis apparatus, in such a way that mechanical movement of moving parts of the synthesizer controls the operation of the cassette from outside the cassette, i.e. externally. [¹⁸F]-radiotracers are now often
25 conveniently prepared on automated radiosynthesis apparatuses. By the term “automated radiosynthesis apparatus” is meant an automated module based on the principle of unit operations as described by Satyamurthy *et al* (1999 Clin Positr Imag; 2(5): 233-253). The term “unit operations” means that complex processes are reduced to a series of simple operations or reactions, which can be applied to a range of
30 materials. Such automated radiosynthesis apparatuses are commercially available from a

range of suppliers (Satyamurthy *et al*, above), including: GE Healthcare; CTI Inc; Ion Beam Applications S.A. (Chemin du Cyclotron 3, B-1348 Louvain-La-Neuve, Belgium); Raytest (Germany) and Bioscan (USA).

A commercial automated radiosynthesis apparatus also provides suitable containers for the liquid radioactive waste generated as a result of the radiosynthesis. Automated radiosynthesis apparatuses are not typically provided with radiation shielding, since they are designed to be employed in a suitably configured radioactive work cell. The radioactive work cell provides suitable radiation shielding to protect the operator from potential radiation dose, as well as ventilation to remove chemical and/or radioactive vapours. Suitable cassettes comprise a linear array of valves, each linked to a port where reagents or vials can be attached, by either needle puncture of an inverted septum-sealed vial, or by gas-tight, marrying joints. Each valve has a male-female joint which interfaces with a corresponding moving arm of the automated radiosynthesis apparatus. External rotation of the arm thus controls the opening or closing of the valve when the cassette is attached to the automated radiosynthesis apparatus. Additional moving parts of the automated radiosynthesis apparatus are designed to clip onto syringe plunger tips, and thus raise or depress syringe barrels.

The cassette is versatile, typically having several positions where reagents can be attached, and several suitable for attachment of syringe vials of reagents or chromatography cartridges (e.g. for SPE). The cassette always comprises a reaction vessel. Such reaction vessels are preferably 0.5 to 10 mL, more preferably 0.5 to 5 mL and most preferably 0.5 to 4 mL in volume and are configured such that 3 or more ports of the cassette are connected thereto, to permit transfer of reagents or solvents from various ports on the cassette. Preferably the cassette has 15 to 40 valves in a linear array, most preferably 20 to 30, with 25 being especially preferred. The valves of the cassette are preferably each identical, and most preferably are 3-way valves. The cassettes are designed to be suitable for radiopharmaceutical manufacture and are therefore manufactured from materials which are of pharmaceutical grade and ideally also are resistant to radiolysis.

Preferred automated radiosynthesis apparatuses of the present invention comprise a disposable or single use cassette which comprises all the reagents, reaction vessels and

apparatus necessary to carry out the preparation of a given batch of the *in vivo* imaging composition of the invention.

The following non-limiting examples serve to illustrate the invention in more detail.

Brief Description of the Examples

- 5 Example 1 describes a method to obtain a composition comprising a compound of Formula I as defined herein and a compound of Formula II as defined herein, wherein a prior art method is compared with the method of the present invention.


List of Abbreviations used in the Examples

OMs: mesylate


- 10 **Example 1: Synthesis of N,N-diethyl-9-(2-[¹⁸F]fluoroethyl)-5-methoxy-2,3,4,9-tetrahydro-1H-carbazole-4-carboxamide**

The compound N,N-diethyl-9-(2-[¹⁸F]fluoroethyl)-5-methoxy-2,3,4,9-tetrahydro-1H-carbazole-4-carboxamide was synthesised using the following steps:




Step 1: Synthesis of ethyl 3-bromo-2-oxocyclohexanecarboxylate




Step 2: Synthesis of N-(2-(benzyloxy)ethyl)-2-chloro-5-methoxyaniline




Step 3: Synthesis of ethyl 3-((2-(benzyloxy)ethyl)(2-chloro-5-methoxyphenyl)amino)-2-

hydroxycyclohex-1-enecarboxylateStep 4: Synthesis of ethyl 9-(2-(benzyloxy)ethyl)-8-chloro-5-methoxy-2,3,4,9-tetrahydro-1H-carbazole-4-carboxylateStep 5: Synthesis of 9-(2-(benzyloxy)ethyl)-8-chloro-5-methoxy-2,3,4,9-tetrahydro-1H-carbazole-4-carboxylic acidStep 6: Synthesis of 9-(2-(benzyloxy)ethyl)-8-chloro-5-methoxy-2,3,4,9-tetrahydro-1H-carbazole-4-carbonyl chloride


10




Step 7: Synthesis of 9-(2-(benzyloxy)ethyl)-8-chloro-N,N-diethyl-5-methoxy-2,3,4,9-tetrahydro-1H-carbazole-4-carboxamide




5 *Step 8: Synthesis of 9-(2-(benzyloxy)ethyl)-N,N-diethyl-5-methoxy-2,3,4,9-tetrahydro-1H-carbazole-4-carboxamide*




Step 9: Synthesis of N,N-diethyl-9-(2-hydroxyethyl)-5-methoxy-2,3,4,9-tetrahydro-1H-carbazole-4-carboxamide



Step 10: Synthesis of 2-(4-(diethylcarbamoyl)-5-methoxy-3,4-dihydro-1H-carbazol-9(2H)-yl)ethyl methanesulfonate



5 Step 11: Synthesis of N,N-diethyl-9-(2-[¹⁸F]fluoroethyl)-5-methoxy-2,3,4,9-tetrahydro-1H-carbazole-4-carboxamide



In the prior art method (Wadsworth *et al* WO 2010/109007 Example 1), intermediate 10
 10 above was purified by crystallization from diethyl ether (Wadsworth *et al* WO
 2010/109007 Example 1(i)). The method of the present invention was carried out as
 generally described by Wadsworth *et al* (WO 2010/109007). However, in the method of


the present invention, intermediate 10 was purified by crystallization from diethyl ether in the presence of diethyl amine.

Table 1: shows the per cent yield of the desired product along with the amount of incorrect isomer impurity (where measured) in brackets thereafter. With the method of the invention it can be seen that the amount of the incorrect isomer in intermediate 10, which was purified using the method of the invention was only 0.2%.

Intermediate	6	7	8	10	12	13
Prior Art	95.10	78.20 (6.4)	90.40 (7.6)	92.18 (7.0)	93.15 (4.9)	91.75 (5.1)
Prior Art	91.28	77.97 (6.9)	82 (9.0)	95.40 (3.2)	91.10 (3.3)	92.87 (2.3)
Invention	95.00 (6.5)	84.00 (6.5)	87.27 (5.8)	97.92 (0.2)	-	-


Claims

- (1) A composition comprising a compound of Formula I:



wherein:

- 5 R¹ is hydrogen, C₁₋₃ alkyl, C₁₋₃ alkoxy, or halo;
- R² is hydroxyl, halo, cyano, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ fluoroalkyl, or C₁₋₃ fluoroalkoxy;
- R³ is -N-R⁷R⁸ wherein R⁷ and R⁸ are hydrogen, C₁₋₆ alkyl, C₇₋₁₀ arylalkyl or, together with R⁷, forms a nitrogen-containing C₄₋₆ aliphatic ring;
- 10 R⁴ is O, S, SO, SO₂ or CH₂;
- R⁵ is CH₂, CH₂-CH₂, CH(CH₃)-CH₂ or CH₂-CH₂-CH₂;
- R⁶ is -A¹-R⁹ wherein A¹ is a bond or C₁₋₁₀ alkylene, and R⁹ is hydrogen, fluoro or a leaving group, or R⁹ is the group -O-R¹⁰ wherein R¹⁰ is hydrogen, C₁₋₃ alkyl, C₃₋₆ aryl, C₇₋₁₀ arylalkyl, or a hydroxyl protecting group;
- 15 wherein said composition comprises no more than 1% of a compound of Formula II:




wherein R^2 to R^6 are as defined for Formula I.

- (2) The composition as defined in Claim 1 wherein R^1 is halo.
- (3) The composition as defined in either Claim 1 or Claim 2 wherein R^1 is chloro or bromo.
- (4) The composition as defined in any one of Claims 1-3 wherein R^1 is chloro.
- (5) The composition as defined in any one of Claims 1-4 wherein R^6 is $-A^1-R^9$ wherein A^1 is C_{1-10} alkylene and R^9 is the group $-O-R^{10}$ wherein R^{10} is C_{7-10} arylalkyl or a hydroxyl protecting group.
- 10 (6) The composition as defined in any one of Claims 1-5 R^6 is $-A^1-R^9$ wherein A^1 is C_{1-10} alkylene and R^9 is the group $-O-R^{10}$ and wherein R^{10} is a hydroxyl protecting group.
- (7) The composition as defined in Claim 1 wherein R^1 is hydrogen.
- (8) The composition as defined in either Claim 1 or Claim 7 wherein R^6 is $-A^1-R^9$ wherein A^1 is C_{1-10} alkylene and R^9 is hydrogen, fluoro or a leaving group.
- 15 (9) The composition as defined in any one of Claims 1, 7 or 8 wherein R^6 is $-A^1-R^9$ wherein A^1 is C_{1-10} alkylene and R^9 is hydrogen.
- (10) The composition as defined in any one of Claims 1, 7 or 8 wherein R^6 is $-A^1-R^9$ wherein A^1 is C_{1-10} alkylene and R^9 is a leaving group.
- (11) The composition as defined in any one of Claims 1, 7 or 8 wherein R^6 is $-A^1-R^9$

wherein A^1 is C_{1-10} alkylene and R^9 is fluoro.


- (12) The composition as defined in any one of Claims 1, 7, 8 or 11 wherein R^6 is $-A^1-R^9$ wherein A^1 is C_{1-10} alkylene and R^9 is [^{18}F]fluoro.
- (13) The composition as defined in any one of Claims 1-12 wherein said composition
5 comprises the S-enantiomer of said compound of Formula I and said compound of Formula II.
- (14) The composition as defined in any one of Claims 1-13 wherein R^6 is $-A^1-R^9$ wherein A^1 is C_{1-3} alkylene.
- (15) The composition as defined in any one of Claims 1-14 wherein R^6 is $-A^1-R^9$ wherein
10 A^1 is ethylene.
- (16) The composition as defined in any one of Claims 1-15 wherein R^2 is halo, C_{1-3} alkoxy or C_{1-3} fluoroalkoxy.
- (17) The composition as defined in any one of Claims 1-16 wherein R^2 is halo or C_{1-3} alkoxy.
- 15 (18) The composition as defined in any one of Claims 1-17 wherein R^2 is fluoro or methoxy.
- (19) The composition as defined in any one of Claims 1-18 wherein R^2 is methoxy.
- (20) The composition as defined in any one of Claims 1-19 wherein R^3 is $-N-R^7R^8$ wherein R^7 and R^8 are C_{1-6} alkyl or C_{7-10} arylalkyl.
- 20 (21) The composition as defined in any one of Claims 1-20 wherein R^3 is $-N-R^7R^8$ wherein R^7 and R^8 are C_{1-3} alkyl.
- (22) The composition as defined in any one of Claims 1-21 wherein R^3 is $-N-R^7R^8$ wherein R^7 and R^8 are both ethyl.
- (23) The composition as defined in any one of Claims 1-22 wherein R^4 is CH_2 .

- (24) The composition as defined in any one of Claims 1-23 wherein R⁵ is CH₂-CH₂.
- (25) The composition as defined in any one of Claims 1-24 which comprises no more than 0.5% of said compound of Formula II.
- (26) The composition as defined in Claim 25 which comprises no more than 0.3% of said compound of Formula II.
- 5 (27) The composition as defined in any one of Claims 1-26 wherein said compound of Formula I is a compound of Formula Ia:



wherein:

- 10 R¹ is as defined in any one of Claims 1-3 and 7;
- R² is as defined in any one of Claims 1 and 16-19;
- R⁷ and R⁸ are as defined in any one of Claims 1 and 20-22;
- R⁹ and A¹ are as defined in any one of Claims 1, 5, 6, 8-12, 14 and 15;
- and said compound of Formula II is a compound of Formula IIa:



wherein each of R^2 , R^7 , R^8 , R^9 and A^1 are as defined for Formula Ia.

(28) The composition as defined in Claim 27 wherein:

R^1 is hydrogen;

5 R^2 is fluoro or methoxy;

R^7 and R^8 are C_{1-6} alkyl;

R^9 is hydrogen, fluoro or a leaving group; and,

A^1 is C_{1-10} alkylene.

(29) The composition as defined in either Claim 27 or Claim 28 wherein:

10 R^1 is hydrogen;

R^2 is methoxy;

R^7 and R^8 are C_{1-3} alkyl;

R^9 is [^{18}F]fluoro or an aryl or alkyl sulfonate; and,

A^1 is C_{1-3} alkylene.

15 (30) The composition as defined in any one of Claims 27-29 wherein:

R¹ is hydrogen;

R² is methoxy;

R⁷ and R⁸ are methyl or ethyl;

R⁹ is [¹⁸F]fluoro, tosylate, triflate, nosylate or mesylate; and,

5 A¹ is C₁₋₃ alkylene.

(31) The composition as defined in any one of Claims 27-30 wherein:

R¹ is hydrogen;

R² is methoxy;

R⁷ and R⁸ are both ethyl;


10 R⁹ is [¹⁸F]fluoro or mesylate; and,

A¹ is ethylene.

(32) A method to obtain the composition as defined in any one of Claims 1-31 wherein
said method comprises crystallization of a reaction mixture comprising said
compound of Formula I as defined in any one of Claims 1-24 and 27-31, and said
15 compound of Formula II as defined in any one of Claims 1, 5, 6, 8-24 and 27-31,
wherein said crystallization is carried out in a suitable organic solvent in the
presence of a catalytic amount of a weak organic base in order to obtain said
composition.

(33) The method as defined in Claim 32 wherein said weak organic base is selected from
20 N,N-diisopropyl ethylamine or diethyl amine.

(34) The method as defined in either Claims 32 or Claim 33 wherein said reaction
mixture is obtained using a method comprising cyclization of a compound of
Formula III:



wherein:

R¹ is as defined in any one of Claims 1-3 and 7;

R² is as defined in any one of Claims 1 and 16-19;

5 R³ is as defined in any one of Claims 1 and 20-22;

R⁴ is as defined in either Claim 1 or Claim 23;

R⁵ is as defined in either Claim 1 or Claim 24; and,

R⁶ is as defined in any one of Claims 1, 5, 6, 8-12, 14 and 15;

10 wherein said cyclization is carried out by reaction of said compound of Formula III with a zinc halide.

(35) The method as defined in Claim 34 wherein said zinc halide is zinc chloride or zinc bromide.

(36) The method as defined in either Claim 34 or Claim 35 wherein said zinc halide is zinc chloride.

15 (37) A pharmaceutical composition comprising the composition as defined in any one of Claims 1-31 together with a biocompatible carrier suitable for mammalian administration.

(38) Use of the pharmaceutical composition as defined in Claim 37 in a medical method.

- (39) The use as defined in Claim 38 wherein said medical method is treatment of a pathological condition.
- (40) The use as defined in Claim 39 wherein said medical method is diagnosis of a pathological condition.
- 5 (41) A method of *in vivo* imaging comprising:
- (i) administering to a subject the pharmaceutical composition as defined in Claim 37 wherein R⁹ is [¹⁸F]fluoro;
 - (ii) detecting signals emitted by the [¹⁸F]fluoro comprised in said pharmaceutical composition;
- 10 (iii) generating an image representative of the location and/or amount of said signals.
- (42) A kit comprising the composition as defined in Claim 1 any one of Claims 1-4, 7, 8, 10 and 13-27 wherein R⁶ is -A¹-R⁹ wherein A¹ is a bond or C₁₋₁₀ alkylene, and R⁹ is a leaving group.
- 15 (43) The kit as defined in Claim 42 which is a cassette for use with an automated radiosynthesis apparatus.

INTERNATIONAL SEARCH REPORT

International application No PCT/EP2013/074986

A. CLASSIFICATION OF SUBJECT MATTER INV. A61K31/403 A61K51/04 C07D209/88 ADD.				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols) C07D				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	HARRY WADSWORTH ET AL: "[18F]GE-180: A novel fluorine-18 labelled PET tracer for imaging Translocator protein 18kDa (TSPO)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 22, no. 3, 1 February 2012 (2012-02-01), pages 1308-1313, XP055100364, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2011.12.084 See also annexed "Supporting Information"; page 1310; table 1; compound 12 -/--	1,5-43		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.				
* Special categories of cited documents : <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; border: none; vertical-align: top;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family </td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family			
Date of the actual completion of the international search	Date of mailing of the international search report			
6 February 2014	17/02/2014			
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Bedel, Christian			

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2013/074986

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>& Harry Wadsworth ET AL: "Supporting Information [18 F]GE-180: A novel fluorine-18 labelled PET tracer for imaging Translocator Protein 18kDa (TSP0)", J CF = 23 Hz), 27 December 2011 (2011-12-27), pages 18-7, XP055100373, Retrieved from the Internet: URL:http://www.sciencedirect.com/science/article/pii/S0960894X11017653 [retrieved on 2014-02-05] ----- WO 2010/109007 A2 (GE HEALTHCARE LTD [GB]; WADSWORTH HARRY JOHN [GB]; O'SHEA DENNIS [GB];) 30 September 2010 (2010-09-30) cited in the application page 33; example 1(i) page 68; example 14 page 13 -----</p>	1-43

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2013/074986

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2010109007	A2	30-09-2010	
		AU 2010227527 A1	13-10-2011
		CA 2756887 A1	30-09-2010
		CN 102448933 A	09-05-2012
		EP 2411362 A2	01-02-2012
		JP 2012521973 A	20-09-2012
		KR 20110133492 A	12-12-2011
		NZ 595227 A	29-11-2013
		RU 2011138850 A	10-05-2013
		SG 174589 A1	28-10-2011
		US 2011070161 A1	24-03-2011
		WO 2010109007 A2	30-09-2010
